Skip to content
Clinical Trials – home

Meldonium Clinical Trials in Heart Failure with Preserved Ejection Fraction

1 / 1
trials open to patients / all trials
1+
Countries

In short

Clinical trials are investigating Meldonium in people with chronic heart failure, especially heart failure with preserved ejection fraction. These studies aim to see whether Meldonium, together with individualized physical activity advice, can improve exercise tolerance and other patient outcomes.

Key points

  • Meldonium is being studied in a Phase 3 trial for people with chronic heart failure with preserved ejection fraction. The study is looking at Meldonium together with individualized physical activity recommendations. The main goal is to see whether this approach improves physical activity tolerance. Researchers are measuring this with a cardiopulmonary test, including VO2 max. The trial is authorised and plans to enroll 200 participants.

Trial overview

This clinical trial is studying Meldonium in patients with chronic heart failure with preserved ejection fraction.

The study is authorised and is designed as an interventional trial, which means the researchers are giving a treatment and then checking the results.

Who is being studied

The target population is people with chronic heart failure with preserved ejection fraction, a form of heart failure where the heart still pumps out a normal-looking amount of blood but does not work properly.

The trial data do not list more detailed participation rules, so the main known group is patients with this heart condition.

What the trial tests

The study is testing Meldonium and individualized physical activity recommendations together in the treatment of these patients.

The brief study summary says the goal is to evaluate effectiveness, which means the researchers want to find out whether this approach helps patients in a real way.

Trial phase and size

This is a Phase 3 study.

Phase 3 studies usually involve more people than early-phase studies and are used to test how well a treatment works in a larger group.

The planned enrollment is 200 participants.

Outcomes being measured

The main outcome is physical activity tolerance, which means how well a person can manage exercise or movement without too much strain.

This is measured by a cardiopulmonary test, including relative maximal oxygen uptake, also called VO2 max.

VO2 max is a way to measure how much oxygen the body can use during exercise, so it helps show exercise capacity.

Questions people often ask

Conditions where Meldonium is being studied

Each condition opens its own overview and trial list

Trials with Meldonium

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).